Products for Research Use Only

Levodropropizine

CAT: 0804-HY-B1895-01Size: 1 gDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1895-01Size:1 g
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Levodropropizine (DF-526) is an orally active histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive agent[1].
CAS Number
99291-25-5
Product Name Alternative
(S) - (-) -Dropropizine; DF-526
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Endocrinology; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Levodropropizine.html
Purity
99.71
Solubility
DMSO : ≥ 50 mg/mL|H2O : 10 mg/mL (ultrasonic)
Smiles
OC[C@@H](O)CN1CCN(C2=CC=CC=C2)CC1
Molecular Formula
C13H20N2O2
Molecular Weight
236.31
Precautions
H302, H315, H319, H335
References & Citations
[1]Zanasi A, et al. Levodropropizine for treating cough in adult and children: a meta-analysis of published studies. Multidiscip Respir Med. 2015 May 31;10 (1) :19.|[2]Luo YL, et al. Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure. Inflamm Res. 2013 Dec;62 (12) :1053-61.|[3]Erdogan MA, et al. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy. Epilepsy Res. 2019 Feb;150:32-37. |[4]Yamawaki I, et al. Levodropropizine reduces capsaicin- and substance P-induced plasma extravasation in the rat trachea. Eur J Pharmacol. 1993 Oct 12;243 (1) :1-6.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched